Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
63.84
-0.64 (-0.99%)
At close: Mar 28, 2025, 4:00 PM
63.00
-0.84 (-1.32%)
After-hours: Mar 28, 2025, 6:54 PM EDT
Halozyme Therapeutics Revenue
In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth. Halozyme Therapeutics had revenue of $298.01M in the quarter ending December 31, 2024, with 29.55% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+22.44%
P/S Ratio
7.97
Revenue / Employee
$2,900,926
Employees
350
Market Cap
7.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHALO News
- 8 days ago - Halozyme Joins the $1 Billion Club - FXEmpire
- 4 weeks ago - Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - PRNewsWire
- 5 weeks ago - Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS - PRNewsWire
- 7 weeks ago - Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - PRNewsWire
- 7 weeks ago - CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - PRNewsWire
- 2 months ago - Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PRNewsWire
- 2 months ago - Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - PRNewsWire